Apexigen resumed with a Buy at Roth Capital

Roth Capital analyst Kumaraguru Raja resumed coverage of Apexigen with a Buy rating and $15 price target. Apexigen is developing sotigalimab, a CD40 agonist therapeutic antibody that activates the immune system. It has activity as a single agent and also works in combination with immune checkpoint inhibitor therapies and chemotherapy. The firms notes that it has shown clinical benefit in melanoma, sarcomas, and other solid tumors. Roth Capital believes that sotigalimab could provide a therapeutic option with better clinical outcomes in advanced cancers with significant unmet need.